Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia

The phosphatidyl-inositol 3 kinase (PI3K) δ inhibitor, idelalisib (IDE), is a potent inhibitor of the B-cell receptor pathway and a novel and highly effective agent for the treatment of chronic lymphocytic leukemia (CLL). We evaluated the activities of IDE in comparison to bendamusine (BEN), a commo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kost, Sara E. F., Saleh, Ali, Mejia, Edgard M., Mostafizar, Marina, Bouchard, Eric D. J., Banerji, Versha, Marshall, Aaron J., Gibson, Spencer B., Johnston, James B., Katyal, Sachin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826782/
https://www.ncbi.nlm.nih.gov/pubmed/31601046
http://dx.doi.org/10.3390/cancers11101519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826782/
https://www.ncbi.nlm.nih.gov/pubmed/31601046
http://dx.doi.org/10.3390/cancers11101519

Ejemplares similares